The safety of topical corticosteroids during pregnancy has been unclear. The U.S. Food and Drug Administration (FDA) classifies these drugs as pregnancy risk category C because animal studies have shown that they adversely affect fetuses, researchers say. However, there are not enough rigorous studies in pregnant women. European Evidence-Based Medical Guidelines for Topical Corticosteroids in Pregnant Women Topical steroid use of any strength in pregnant women is not associated with fetal orofacial clefts, preterm labor, and stillbirth. Topical use of weakly/moderately potent steroids was not significantly associated with fetal growth restriction; topical use of ultra/strongly potent steroids was significantly associated with fetal growth restriction; and a nationwide retrospective cohort study in Denmark showed no correlation with cleft palate and no support for a dose-dependent relationship between cleft lip and palate when corticosteroids were used topically in the first trimester of pregnancy in 22,480 cases. Mild/moderate topical corticosteroids may be used when needed during pregnancy (recommendation level B). Whereas, super potent/strong topical corticosteroids should be used for as short a period of time as possible or as a second-line medication (Recommendation Level B). It is also necessary to use effective smaller doses of topical corticosteroids as appropriate to the severity of your skin condition, following medical advice and strictly adhering to the prescribed limitations on dosage and duration of use. High absorption areas such as flexural areas, axilla and pubic area should be used more cautiously. Another SCI paper published by Dr. Shu-Huei Wang in Taiwan analyzed a retrospective study of 2,658 pregnant women who used topical corticosteroids and 7,246 pregnant women who did not use steroids. Its results showed no relationship between topical corticosteroids and very few post-pregnancy outcomes, including facial clefts, low birth weight, preterm labor, and fetal death. However, the use of potent or ultra-potent topical corticosteroids in doses of 300 grams or more throughout pregnancy was associated with a significantly increased risk of low birth weight in infants. When the total use is less than 200 grams, there is no increased risk of low birth weight. Therefore, it was concluded that the short-term use of typical standard doses of corticosteroid creams during pregnancy had no significant effect on fetal growth and development.